Tivozanib vs sorafenib (targeted agent versus targeted agent)Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)1 finding from 1 reviewTargeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 506 participantsLow